Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on February 22, 2023, covering events occurring on February 17, 2023. The filing discloses a significant change in executive leadership, specifically the appointment of Robert J. Bitterman as President, Chief Executive Officer, and Chair of the Board, effective February 20, 2023.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment terms.
- Base Salary: $440,000 annually.
- Annual Bonus: Eligible for up to 40% of base salary based on performance goals.
- Equity Grant: 11,000 Restricted Stock Units (RSUs) under the 2020 Long Term Incentive Plan.
- Vesting Schedule: RSUs vest in two equal annual installments commencing on the first anniversary of the grant date.
Material Changes
The primary material change is the transition of Robert J. Bitterman from acting Executive Chairman and acting Interim CEO to the permanent roles of President, CEO, and Chair of the Board. He continues to serve as the Company's principal executive officer and principal financial officer. This appointment follows his service as Interim Executive Chairman since September 2022.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or discuss specific business risks. It details the terms of the new Employment Agreement, including severance provisions:
- Death or Disability: Payment of accrued benefits and pro-rata vesting of all equity awards.
- Termination for Cause or Without Good Reason: Payment of accrued benefits only.
- Termination for Good Reason or Without Cause: Accrued benefits, three months of base salary, accrued bonus, and full vesting of equity awards if the termination occurs within one year of a Change in Control.
Investor Verification Checklist
- Verify the effective date of the CEO appointment (February 20, 2023) and the associated press release (Exhibit 99.1).
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific performance goals tied to the bonus structure.
- Confirm the vesting schedule and conditions for the 11,000 RSUs granted to Mr. Bitterman.
- Check for any subsequent filings regarding the company's financial status, as this 8-K contains no financial data.